Edition:
United States

Pacira Pharmaceuticals Inc (PCRX.OQ)

PCRX.OQ on NASDAQ Stock Exchange Global Select Market

47.45USD
4:00pm EDT
Change (% chg)

$-0.40 (-0.84%)
Prev Close
$47.85
Open
$47.85
Day's High
$48.00
Day's Low
$47.05
Volume
260,794
Avg. Vol
228,083
52-wk High
$58.80
52-wk Low
$30.00

PCRX.OQ

Chart for PCRX.OQ

About

Pacira Pharmaceuticals, Inc. is a holding company. The Company is a pharmaceutical company focused on the development, manufacture and commercialization of pharmaceutical products, based on its DepoFoam extended release drug delivery technology, for use primarily in hospitals and ambulatory surgery centers. Its lead product... (more)

Overall

Beta: 2.17
Market Cap(Mil.): $1,918.49
Shares Outstanding(Mil.): 40.09
Dividend: --
Yield (%): --

Financials

  PCRX.OQ Industry Sector
P/E (TTM): -- 14.08 19.12
EPS (TTM): -1.44 -- --
ROI: -13.50 -6.75 -5.05
ROE: -21.72 -6.20 -4.29

BRIEF-Pacira Pharma says President James Scibetta has resigned

* Pacira pharmaceuticals -james scibetta resigning as president to become ceo of an undisclosed private early-stage oncology company

May 23 2017

BRIEF-Pacira Pharmaceuticals Inc reports Q1 GAAP loss per share $0.52

* Pacira pharmaceuticals, inc. Reports first quarter 2017 financial results

May 04 2017

BRIEF-Trinity and Pacira announce collaboration to decrease opioid use nationwide

* Trinity Health and Pacira Pharmaceuticals announce collaboration to decrease opioid use nationwide

Mar 16 2017

BRIEF-Pacira says phase 4 study shows its drug reduces opioid consumption and postsurgical pain in patients undergoing total knee arthroplasty

* Phase 4 study shows exparel versus active comparator reduces opioid consumption and postsurgical pain in patients undergoing total knee arthroplasty

Mar 14 2017

BRIEF-Pacira Pharmaceuticals prices $300 mln aggregate principal amount of 2.375% convertible senior notes due 2022

* Pacira Pharmaceuticals announces pricing of $300 million aggregate principal amount of 2.375% convertible senior notes due 2022 Source text for Eikon: Further company coverage:

Mar 08 2017

BRIEF-Pacira Pharmaceuticals announces proposed offering of $300 million aggregate principal amount of convertible senior notes

* Announces proposed offering of $300 million aggregate principal amount of convertible senior notes

Mar 06 2017

BRIEF-Pacira Pharmaceuticals reports Q4 adj. earnings per share $0.09

* Pacira Pharmaceuticals reports 2016 financial results and provides business update

Mar 01 2017

BRIEF-Pacira Pharmaceuticals collaborates with Depuy Synthes to support promotion, education and training of exparel in orthopedics

* Pacira Pharmaceuticals announces collaboration with Depuy Synthes to support promotion, education and training of Exparel in orthopedics

Jan 25 2017

More From Around the Web

Competitors

Earnings vs. Estimates